Cat. No. 3135
Chemical Name: 6-(Cyclohexylmethoxy)-9H-purin-2-am
Biological ActivityCyclin-dependent kinase (cdk) 1 and cdk2 inhibitor (Ki values are 5 and 12 μM respectively). Inhibits growth of human tumor cells in vitro (mean GI50 = 13 μM). Also inhibits DNA topoisomerase II ATPase activity (IC50 = 300 μM).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Jensen et al (2005) Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors. Cancer Res. 65 7470. PMID: 16103101.
Knockaert et al (2002) Pharmacological inhibitors of cyclin-dependent kinases. TiPS 23 417. PMID: 12237154.
Arris et al (2000) Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J.Med.Chem. 43 2797. PMID: 10956187.
If you know of a relevant reference for NU 2058 please let us know.
Citations are publications that use Tocris products. Selected citations for NU 2058 include:
Goonesekere et al (2014) A meta analysis of pancreatic microarray datasets yields new targets as cancer genes and biomarkers. PLoS One 9 e93046. PMID: 24740004.
Do you know of a great paper that uses NU 2058 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: NU 2058, supplier, Cdk1, cdk2, Topoisomerase, II, inhibits, inhibitors, Cyclin-Dependent, Protein, Kinases, DNA, Isomerases, NU2058, Tocris Bioscience, Cyclin-Dependent Protein Kinase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent Syk kinase inhibitor; also inhibits assembly of NLRP3 inflammasomesSTK16-IN-1
Serine/threonine protein kinase 16 (STK16) inhibitor; also inhibits P13Kδ, P13Kγ and mTOR kinases.AZ PFKFB3 26
Potent and selective PFKFB3 inhibitorNCL 00017509
Potent and reversible NIMA related kinase 2 (Nek2) inhibitorXMD 8-87
Potent Ack1/TNK2 inhibitorSKI 178
Non-lipid sphingosine kinase 1 (SphK1) inhibitorML 315 hydrochloride
Inhibitor of Clk and DYRK kinasesEverolimus
mTOR inhibitor;immunosuppressantPKI (5-24)
High affinity PKA inhibitorTDZD 8
Selective non-ATP competitive inhibitor of GSK 3βBI 605906
Selective IKKβ inhibitorGSK 319347A
Potent and selective IKKε inhibitorFRAX 597
Potent group I PAK inhibitorMRT 68921 dihydrochloride
Potent ULK inhibitor; inhibits autophagyAM 2394
Potent glucokinase activator; orally bioavailableeCF 309
Potent mTOR inhibitorPF 3758309 dihydrochloride
Potent PAK4 inhibitor; orally availableAZ Dyrk1B 33
Potent and selective Dyrk1B kinase inhibitorPF 06409577
Potent and selective allosteric activator of AMPKPerifosine
PKB/Akt inhibitor; also modulates Kv2.1 currentRAF 265
Raf kinase and VEGFR-2 inhibitorCZC 25146
Potent LRRK2 inhibitorRo 3280
Potent and selective PLK1 inhibitorRMM 46
MSK/RSK family kinase inhibitor
August 20 - 24, 2017
Paris , France